Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Conditioning and Haploidentical Bone Marrow Transplant for High-risk Solid Tumors
NCT01804634Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2013
- Primary completion
- Jan 2027
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, tacrolimus in solid tumor, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Mar 2013; status: recruiting.
02
Drugs
cyclophosphamidetacrolimus
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT01804634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01804634.